RESUMO
Objective To investigate the expression of soluble transferrin receptor(sTfR)and fibroblast growth factor 22(FGF22)in serum of first-episode schizophrenia(FES)patients,analyze the relationship be-tween the two and the clinical symptoms of FES patients,and analyze their diagnostic value.Methods A total of 97 FES patients diagnosed in the hospital from March 2021 to February 2023 were regarded as the FES group,during the same period,96 healthy volunteers who came to this hospital for physical examination were regarded as the control group.Immunotransmission turbidimetry was applied to detect the level of sTfR,en-zyme linked immunosorbent assay(ELISA)was applied to detect the level of FGF22,Spearman method was applied to analyze the correlation between the levels of sTfR and FGF22 in the serum of FES patients and Pos-itive and Negative Syndrome Scale(PANSS)score and Wisconsin Card Sorting Test(WCST)results,and re-ceiver operating characteristic(ROC)curve was applied to analyze the clinical diagnostic value of levels of sTfR and FGF22 for FES.Results There were no obvious differences between the two groups in terms of gender,age,body mass index,years of education,history of alcohol consumption,and smoking history(P>0.05).Compared with the control group,the serum levels of sTfR and FGF22 in the FES group were obvious-ly lower(P<0.05).The area under the curve(AUC)of sTfR for diagnosing FES alone was 0.835,with the cut off value of 4.606 mg/L,the AUC of FGF22 for diagnosing FES alone was 0.772,with the cut off value of 208.333 μg/L,the AUC of the combination of the two(0.921)was obviously higher than that of sTfR alone(Z=2.613,P=0.009),and that of FGF22 alone(Z=5.140,P<0.001).The PANSS positive symptom score,negative symptom score,pathological symptom score,total score,WCST persistent errors,and incorrect responses in the high sTfR level group and high FGF22 group were lower than those in the low sTfR group and low FGF22 group(P<0.05),while the number of WCST completed classifications and WCST correct re-sponses were higher than those in the low sTfR group and low FGF22 group(P<0.05).The levels of sTfR and FGF22 in the FES group were negatively correlated with PANSS positive symptom score,negative symp-tom score,pathological symptom score,total score,WCST persistent errors,and WCST incorrect responses(P<0.05),and positively correlated with the number of WCST completed classifications and WCST correct responses(P<0.05).Conclusion The levels of sTfR and FGF22 in the serum of FES patients are obviously decreased.Combined detection of sTfR and FGF22 levels is of great significance for the clinical diagnosis of FES.
RESUMO
Objective:To ulteriorly explore the differences of psychotic symptoms and neurocognitive between patients with first-episode deficit subtype of schizophrenia (FDS) and patients with first-episode nondeficit subtype of schizophrenia (FNDS).Methods:From January 2021 to September 2021, a total of 88 first-episode treatment-naive schizophrenia were recruited from the Mental Health Center of West China Hospital and divided into FDS group( n=44) and FNDS group( n=44) according to the schedule for the deficit syndrome (SDS), and 44 healthy subjects were included as healthy control group (HC group, n=44). Positive and negative syndrome scale (PANSS) was used to assess psychotic symptoms of patients and Wechsler adult intelligence scale, trail making test and logic memory test were used to evaluate intelligence quotient and neurocognitive function of all subjects.SPSS 22.0 was used for statistical analysis, and independent samples t-test and one-way analysis of variance (ANOVA) were used to compare variables that met normal distribution, while the Mann-Whitney U test and Kruskal-Wallis H test were used to compare variables that did not meet normal distribution. Results:(1) There were significant differences in psychotic symptoms between the FDS group and the FNDS group.Compared with the FNDS group, the FDS group had higher total score of PANSS ((95.95±16.82) vs (88.39±16.29)), negative symptoms ((27.57±7.52) vs (16.57±5.76)) and anergastic reaction ((13.43±3.82) vs (7.00(5.00, 9.00)), and lower positive symptoms scores ((21.95±6.88) vs (25.41±6.07)), activation ((8.00(5.00, 9.00) vs (9.27±3.47)), depression ((5.50(4.00, 9.00) vs (8.00(6.00, 12.00)) and supplementary item ((13.60±4.17) vs (17.30±5.39))(all P<0.05). (2) There were differences in neurocognitive functions between FDS group and FNDS group, and which in FDS and FNDS group were worse than that in HC group.Spatial memory (block design test: (23.70±11.05) vs (31.72±11.49)) and information processing speed (digit symbol test: (38.38±15.85) vs (47.97±14.99)) of FDS group were significantly lower than those of FNDS group(both P<0.05). Intelligence quotient, information processing speed and spatial memory of FDS group and FNDS group were lower than those of HC group(all P<0.05). Conclusion:FDS patients has more severe negative symptoms and anergastic reaction, and exit worse information processing speed and spatial memory dysfunction than FNDS patients.This unique pattern of impairment suggests that information processing speed and spatial memory may be important classification indicators for differentiating the deficit subtype of schizophrenia in the early stage.
RESUMO
Objective:To investigate the clinical efficacy of risperidone combined with olanzapine in the treatment of first-episode schizophrenia and its effects on serum homocysteine level and cognitive function.Methods:Sixty patients with first-episode schizophrenia who received treatment in Yiwu Mental Health Center from May 2017 to May 2018 were included in this study. They were randomly assigned to receive either olanzapine (control group, n = 30) or olanzapine and risperidone (observation group, n = 30) treatment. All patients received 4 weeks of treatment. We compared serum homocysteine level, cognitive function, and clinical efficacy between the two groups. Results:There was no significant difference in serum homocysteine level pre-treatment between the two groups ( P > 0.05). Serum homocysteine level post-treatment was significantly lower in the observation group than in the control group [(13.59 ± 2.61) mmol/L vs. (15.83 ± 2.58) mmol/L, t = 3.34, P < 0.05). There were no significant differences in the scores of each cognitive function item pre-treatment between the two groups (all P > 0.05). The scores of each cognitive function item post-treatment in the observation group was (15.06 ± 2.28) points, (21.18 ± 3.26) points, (44.39 ± 4.42) points, (40.63 ± 6.27) points, which were significantly superior to those in the control group [(13.31 ± 2.04) points, (19.26 ± 3.07) points, (42.43 ± 2.07) points, (44.19 ± 5.86) points, t = 3.13, 2.34, 2.12, 2.27, all P < 0.05]. The total improvement rate was significantly higher in the observation group than in the control group [93.33% (28/30) vs. 70.00% (21/30), χ2 = 5.45, P < 0.05). Conclusion:Risperidone combined with olanzapine is highly effective on first-episode schizophrenia. The combined therapy can reduce serum homocysteine level and improve cognitive function.
RESUMO
ObjectiveTo explore the effects of group interpersonal psychotherapy （IPT） on cognitive and social function in patients with first-episode schizophrenia， and to provide references for appropriate psychological treatment for the patients. MethodsA total of 62 patients with first-episode schizophrenia who met the diagnostic criteria of International Classification of Diseases， tenth edition （ICD-10） and were admitted to the Third People's Hospital of Foshan from January to December 2021 were selected as the study objects. And patients were divided into study group and control group according to random number table method， each with 31 cases. Both groups were treated with risperidone for 8 weeks， based on this， study group received group IPT. Before and after 8 weeks of treatment， Positive and Negative Syndrorne Scales （PANSS）， Wisconsin Card Sorting Tests （WCST） and Personal and Social Performance Sale（PSP） were adopted to assess the patients' psychiatric symptoms， cognitive function and social function. ResultsAfter 8 weeks of treatment， there was no significant difference in PANSS scores between the two groups （t=0.296， P>0.05）. The WCST total number of responses in the study group was larger than that in the control group， the number of perseverative errors and non-perseverative errors were smaller than those in the control group， and PSP score of the study group was higher than that of the control group， with statistically significant differences （t=0.398， 2.609， 0.523， 0.381， P<0.05 or 0.01）. ConclusionGroup IPT may have no significant efficacy on alleviating the symptoms of patients with first-episode schizophrenia， but it may help improve the cognitive and social function in patients.
RESUMO
ABSTRACT Background: To scale up the services for first-episode schizophrenia in Thailand, it is essential to understand to what extent health care-seeking is delayed, and how much the delay affects the treatment outcome. Objectives: To investigate the duration of untreated psychosis (DUP) and its impact on remission in first-episode schizophrenia across the country. Methods: 276 outpatients with a first-episode schizophrenia were followed for 6 months and assessed whether they fulfilled the criteria for remission at the follow-up. The proportion of those achieving remission was compared by the DUP. The impact of DUP on remission was estimated in multivariate analyses. Results: At the follow-up, 83% (71/86) of patients who had met the criteria for symptomatic remission at the baseline achieved enduring remission, whereas 63% (119/190) of patients who had not met the criteria for symptomatic remission at baseline met it at the follow-up. The shorter the DUP, the higher the proportion of those who achieved symptomatic or enduring remission at the follow-up. The impact of DUP on symptomatic remission appeared to be significant after controlling for other factors influencing remission. Conclusion: Since the DUP would influence remission of patients with schizophrenia, early detection and intervention services should be provided in Thailand.
RESUMO
OBJECTIVES@#To explore the metabolite characteristics in medial prefrontal cortex (mPFC) by @*METHODS@#A total of 46 patients with the first-episode schizophrenia (FES), 49 people with clinical high risk (CHR), 61 people with genetic high risk (GHR), and 58 healthy controls (HC) were enrolled. The levels of N-acetylaspartylglutamate+N-acetylaspartate (tNAA), choline-containing compounds (Cho) and myo-inositol (MI), glutamate+glutamine (Glx) in medial prefrontal cortex were measured by single-voxel @*RESULTS@#There were significant differences in Glx, tNAA, and MI concentrations among 4 groups (all @*CONCLUSIONS@#The decreased levels of MI and Glx in the FES patients suggest that there may be glial functional damage and glutamatergic transmitter dysfunction in the early stage of the disease. The compensatory increase of metabolites may be a protective factor for schizophrenia in the genetic individuals.
Assuntos
Humanos , Ácido Aspártico , Ácido Glutâmico , Glutamina , Imageamento por Ressonância Magnética , Espectroscopia de Ressonância Magnética , Espectroscopia de Prótons por Ressonância Magnética , EsquizofreniaRESUMO
Objective To explore the characteristics of blood lipid level and cognitive impairment in first-episode schizophrenic patients with positive and negative symptoms, and their correlation. Meth-ods Seventy inpatients with first-episode schizophrenia were enrolled in the hospital. Their psychiatric symptoms were assessed by positive and negative syndrome scale ( PANSS). They were divided into two groups: positive symptoms group with 42 patients and negative symptoms group with 28 patients. All patients were assessed with the Chinese version of the measurement and treatment research to improve cognition in schizophrenia consensus cognitive battery (MCCB). The differences and characteristics of cognitive function between the two groups were compared. Body mass index (BMI),serum triglyceride,total cholesterol,low density lipoprotein and high density lipoprotein were recorded at admission,and the results were compared between the two groups. The correlation between cognitive assessment scores and metabolic indicators intra groups were analyzed using pearson correlation analysis. Results The scores of trail making test( TMT), brief assessment of cognition in schizophrenia-symbol encoding(BACS),Hopkins verbal learning test,maze and continuous performance test-identical pairs ( CPT-IP) in positive group (( 27. 13 ± 6. 89), ( 32. 97 ± 13. 69),(35. 70 ± 7. 52),(32. 63 ± 4. 59),( 33. 35 ± 11. 10)) were higher than those in negative group ((12. 90±14. 72),(19. 90±11. 98),(25. 80±5. 44),( 27. 50±5. 20),( 19. 89±11. 29),all P<0. 05). In terms of BMI and lipid metabolism indicators,the total cholesterol and low-density lipoprotein levels in the negative group ((5. 03± 1. 42),( 3. 04 ± 1. 18)) were higher than those in the positive group ((4. 18± 0. 78),(2. 45±0. 64)),and the difference was statistically significant (P<0. 05). In negative group,total cholesterol and low density lipoprotein were negatively correlated with the scores of TMT ( r=-0. 469,-0. 751),BACS( r=-0. 517,-0. 538) and CPT-IP ( r=-0. 495,-0. 542) in cognitive function(all P<0. 05). Conclusion First-episode schizophrenia patients with positive and negative symptoms have similar lesion dimensions in cognitive function, but patients with negative symptoms are more severely impaired. There are differences in lipid metabolism between first-episode schizophrenia patients with positive dominant symptoms and negative dominant symptoms,and the lipid metabolism of first-episode schizophrenia patients with negative dominant symptoms is related to cognitive function.
RESUMO
Objective@#To explore the characteristics of blood lipid level and cognitive impairment in first-episode schizophrenic patients with positive and negative symptoms, and their correlation.@*Methods@#Seventy inpatients with first-episode schizophrenia were enrolled in the hospital.Their psychiatric symptoms were assessed by positive and negative syndrome scale (PANSS). They were divided into two groups: positive symptoms group with 42 patients and negative symptoms group with 28 patients.All patients were assessed with the Chinese version of the measurement and treatment research to improve cognition in schizophrenia consensus cognitive battery (MCCB). The differences and characteristics of cognitive function between the two groups were compared.Body mass index (BMI), serum triglyceride, total cholesterol, low density lipoprotein and high density lipoprotein were recorded at admission, and the results were compared between the two groups.The correlation between cognitive assessment scores and metabolic indicators intra groups were analyzed using pearson correlation analysis.@*Results@#The scores of trail making test(TMT), brief assessment of cognition in schizophrenia-symbol encoding(BACS), Hopkins verbal learning test, maze and continuous performance test-identical pairs(CPT-IP) in positive group((27.13±6.89), (32.97±13.69), (35.70±7.52), (32.63±4.59), (33.35±11.10)) were higher than those in negative group ((12.90±14.72), (19.90±11.98), (25.80±5.44), (27.50±5.20), (19.89±11.29), all P<0.05). In terms of BMI and lipid metabolism indicators, the total cholesterol and low-density lipoprotein levels in the negative group ((5.03±1.42), (3.04±1.18)) were higher than those in the positive group ((4.18±0.78), (2.45±0.64)), and the difference was statistically significant (P<0.05). In negative group, total cholesterol and low density lipoprotein were negatively correlated with the scores of TMT(r=-0.469, -0.751), BACS(r=-0.517, -0.538) and CPT-IP(r=-0.495, -0.542) in cognitive function(all P<0.05).@*Conclusion@#First-episode schizophrenia patients with positive and negative symptoms have similar lesion dimensions in cognitive function, but patients with negative symptoms are more severely impaired.There are differences in lipid metabolism between first-episode schizophrenia patients with positive dominant symptoms and negative dominant symptoms, and the lipid metabolism of first-episode schizophrenia patients with negative dominant symptoms is related to cognitive function.
RESUMO
Objective • To explore the relationship between θ oscillation of auditory event-related potential P300 and clinical symptoms in the patients with clinical high risk (CHR) of psychosis or first episode schizophrenia (FES). Methods • A total of 18 patients with CHR of psychosis (CHR group), 18 patients with FES (FES group) and 19 healthy controls (control group) were recruited to complete the standard auditory Oddball paradigm as well as electroencephalogram (EEG) recording with 64-channel EEG cap. Fz, Cz and Pz electrodes were selected to compare the amplitudes and peak latent periods among the three groups, and time-frequency analysis of the θ oscillation in P300 was performed. Results • There was significant difference in the amplitudes of P300 among the three groups (P=0.004). The amplitudes of P300 in FES group (P=0.001) and CHR group (P=0.026) were both significantly lower than that of control group. There was no difference between CHR group and FES group in P300 amplitude (P>0.05). θ Oscillation induced power was significantly different among the three groups (P=0.022). The induced power value of FES group was significantly lower than that of control group (P=0.008); and it was marginally lower in CHR group as compared to that of control group (P=0.054). There was no difference between CHR group and FES group (P>0.05). There was trending difference in θ oscillation evoked power among the three groups (P=0.054). The correlation analysis showed that the total and subscale scores of Positive and Negative Syndrome Scale in FES group were significantly correlated with the amplitudes of P300 at Cz and Pz electrodes (P<0.05). Conclusion • There are significant abnormalities in the amplitude of auditory P300 and θ oscillation of P300 in both CHR and FES patients; however, the change in CHR patients is less severe than that of FES patients. The impaired θ oscillation of P300 in CHR patients is limited to induced power, but evoked power is not impaired.
RESUMO
Objective To investigate the difference of the motif patterns in brain directed functional network between first-episode schizophrenia patients and healthy controls, and to analysis the alterations of the underlying information flow patterns in patient networks. Methods The resting-state functional MRI data were collected from 44 first-episode schizophrenia patients and 39 healthy controls. The convergent cross mapping approach was employed to measure the causality connections between brain regions, and the directed functional networks were constructed. The calculations of the frequency and probability spectrum of all motif classes were performed at both whole brain and modular connected level. The between-group difference was then calculated. Results Compared with healthy controls, the frequency spectrum values of all motif classes in schizophrenia were significantly reduced (P＜0.05, FDR corrected), the Z scores of frequency spectrum of were decreased in chain-like motifs and increased in loop-like motifs. In the two groups, the probability values were higher at modular level than at whole brain level in two loop-like motifs (P＜0.05). Conclusion The present study revealed a loss in brain directed functional connections and abnormal alterations in the basic information flow patterns in first-episode schizophrenia brain.
RESUMO
Objective:To explore the characteristics of cognitive function in patients with early onset and adult onset schizophrenia.Methods:In this cross-sectional study, 546 patients with schizophrenia who met the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-Ⅳ) were selected.Among them, 62 cases were defined as early onset schizophrenia (EOS, age of onset＜18 years) and 175 patients were defined as adult onset schizophrenia (AOS, age of onset≥25 years).Patients underwent clinical assessments with the Positive and Negative Symptom Scale (PANSS) and the Personal and Social Performance Scale (PSP), and comprehensive neuropsychological assessments.Results:The EOS patients got lower scores in motor function-PEGDOM T score [ (26±12) vs. (30±11), P＜0.01], working memory-average T score of PASAT and WMSSP[ (34±12) vs. (38±10), P＜0.05]and executive function (inhibition) -Stroop T score [ (35±12) vs. (39±10), P＜0.05]than AOS patients.No differences were fund in processing speed, verbal memory and learning, visual memory and learning (Ps＞0.05) between the two groups.Conclusion:It suggests that the EOS patients have worse motor function, working memory and inhibition.
RESUMO
Aims:To compare the effect of risperidone and cloazpine on executive functioning in treatment naïve first episode schizophrenia. Methods: A total of 55 treatment naïve first episode patients of schizophrenia as per ICD-10 criteria, were enrolled for the study. Baseline assessment for executive functioning was carried out with TMT- A& B. Clozapine and risperidone were used in the range of 200-600mg/ day and 4- 8 mg/day respectively for 6 months. Results: There was significant improvement in executive functioning in both the groups and the results were statistically significant for clozapine on TMT-B. Conclusion: The findings of current study show that both risperidone and clozapine lead to improvement in executive functioning in first episode of schizophrenia and clozapine fared better than risperidone.
RESUMO
Objective To explore the influence of duration of untreated psychosis (DUP)on cognition and social function in first-episode drug-na?ve schizophrenia. Methods Ninety-three first-episode drug-na?ve schizophrenic were enrolled as the schizophrenia group and 93 normal people served as the control group. The Positive and Negative Symptoms Scale (PANSS) were used to assess the degree of mental symptoms. The Matrics Consensus Cognitive Battery (MCCB) was used to evaluate the cognitive function. Personal and Social Performance Scale (PSP) and the Global Assessment Function Scale (GAF) were used to evaluate the social function. Result There were significant differences in scores of Trail Marking Test, Symbol Coding test, Category Fluency test, Stroop color word test, Continuous Performance Test, Spatial Span test, Brief-Visuospatial Memory Test-Revised (HVLT-R), Brief-Visuospatial Memory Test-Revised (BVMT-R) and Maze test between the schizophrenia group and the control group (all P<0.05). There were significant differences in scores of GAF and PSP between the schizophrenia group and the control group (all P<0.05). DUP was negatively related to the score of HVLT-R2 (r=-0.265, P=0.010) or BVMT-R3 (r=-0.328, P=0.001). DUP was negatively related to the scores of GAF score(r=-0.292,P=0.005)or PSP score(r=-0.397,P<0.001). Conclusion There are social function impairment and a wide range of cognitive function impairment in the first-episode drug-na?ve schizophrenic. The length of the DUP is associated with the severity of the social functional and cognitive functional impairment.
RESUMO
Objective To explore the relationship between the levels of serum BDNF,IL-6 and Hcy with cognitive impairment in the patients with first episode schizophrenia.Methods One hundred and thirty-five patients with schizophrenia(patients group)and 130 mental healthy volunteers (control group)in our hospital from January 2015 to January 2016 were selected as the research sub-jects.The levels of IL-6 and BDNF were detected by adopting the enzyme linked immunosorbent assay (ELISA)and Hcy level was detected by using the circulating enzymatic method.The mental symptoms were evaluated by the positive and negative symptom rat-ing scale (PANSS),cognitive function was evaluated by the Wisconsin Card Sorting Test (WCST)and their relationship was ana-lyzed.Results The BDNF level in the patients group was significantly lower than that in the control group,while the Hcy and IL-6 levels were significantly higher than those in the control group,the differences were statistically significant(P<0.05).The WCST errors response number,persistent errors number and total responses number in the patients group were significantly higher than those in the control group,while the complete classification number and correct response number were significantly lower than those in the control group,the differences were statistically significant (P<0.05).The levels of BDNF,IL-6 and Hcy had significant cor-relation with the WCST total responses number,persistent errors number,errors response number and complete classification num-ber.Conclusion The levels of serum Hcy,IL-6 and BDNF in the patients with first episode schizophrenia have a certain relation with the mental symptoms and cognitive function,which demonstrates the existence of nerve-humor-immune regulation network regulation mechanism in a certain degree and plays a synergic action in the occurrence and development of schizophrenia.
RESUMO
Objective To investigate the influence of ziprasidone combined with amend electric shock on the efficacy and metabolism of patients with first-episode schizophrenia.Methods According to random number table,86 cases with first-episode schizophrenia from July 2013 to July 2016 in the Second Affiliated Hospital of Xinxiang Medical University were chosen and divided into observation group and control group.The patients in observation group were given ziprasidone combined with first-episode schizophrenia,the patients in control group were taken with olanzapine combined with first-episode schizophrenia.The PANSS total score,CGI score,total efficacy,adverse reaction,body mass index,glycometabolism,and lipid metabolism of two groups were observed and compared.Results The PANSS score,CGI score of two groups were all obvious decreased,which had no significant difference,the total efficacy of two groups had no significant difference;The TESS scores were all decreased,and the TESS score of observation group was obviously lower than that of control group (P ＜ 0.05).Compared with before treatment,the BMI,fasting blood sugar,triglyceride,total cholesterol,high/low density lipoprotein and fasting insulin level of observation group after treatment had no obvious significant difference,while the BMI,fasting blood sugar,triglyceride,total cholesterol,low density lipoprotein,and fasting insulin levels of control group had obvious significant difference,and the BMI,fasting blood sugar,triglyceride,total cholesterol,and fasting insulin of observation group were obviously lower than control group (P ＜ 0.05).Conclusion Olanzapine and ziprasidone combined with amend electric shock have obvious efficacy on patients with first-episode schizophrenia,while the ziprasidone had lower adverse reaction and metabolic side effects,which is worth of clinical promotion and application.
RESUMO
Objective To investigate the efficacy of sulforubicin combined with olanzapine in the treatment of adolescents with schizophrenia and to observe its effect on cognitive function.MethodsFrom August 2013 to August 2016, 124 adolescents diagnosed with schizophrenia were randomly divided into control group and observation group,each of 62 cases.The control group was given olanzapine treatment, the observation group was given olanzapine combined with amisulpride treatment.Positive and negative symptom scale (PANSS), Wisconsin Card Sorting Test (WCST) and Wechsler Memory Scale (WMS) were used to evaluate the patient and clinical symptoms and cognitive function after 8 weeks of treatment The clinical effect and adverse changes of two groups were compared.ResultsThe PANSS score, WCST score and WMS score of the two groups were not statistically significant.After 8 weeks of treatment, the PANSS score, WCST score and WMS score of the two groups were significantly higher than those before treatment (P<0.05), and the improvement of the above scores in observation group was better than that of the control group (P<0.05).The total effective rate was 93.55% in the observation group, which was significantly higher than that in the control group (67.74%, χ2=14.49, P<0.05).There was no serious adverse reaction between the two groups.ConclusionThe combination of sulforubicin and olanzapine for the first episode of schizophrenia is very effective in improving the clinical symptoms and cognitive function of patients, and has better safety.
RESUMO
Objective To investigate the clinical significance of plasma neuropeptide Y (NPY)and oxytocin (OXT) and the mRNA level of OXT gene in first-episode schizophrenia (FES) patients and healthy controls (HC).Methods The plasma concentration of NPY and OXT in 55 FES patients and 33 HC were measured by enzyme linked immunosorbent assay (ELISA) and the mRNA level of OXT gene were performed by real-time quantitative polymerase chain reaction (RT-qPCR).Results The NPY levels in FES patients ((1386.88±254.57) pg/ml) were significantly higher than that in HC ((1 140.62±266.63)pg/ml)(P＜0.01),and both the males and females in FES patients ((1 489.97±231.06)pg/ml and (1 279.97±236.30) pg/ml) were higher than their counterparts in HC ((1 305.40 ± 238.80) pg/ml and (965.55 ±165.45) pg/ml) (P＜0.05,P＜0.01).The OXT level in FES patients ((553.26± 180.49) pg/ml) was lower than that in HC ((696.27±280.77) pg/ml) with significant difference (P＜0.05),especially the females FES patients ((597.49±178.63)pg/ml vs (785.51±329.60)pg/ml);but the mRNA expression of OXT gene in FES patients (0.2075 (0.1653,0.3388)) were significantly higher than that in HC (0.1615 (0.1321,0.2200)) (P＜0.05),and there were no differences between the females of the two groups (P＞0.05).Conclusion The FES patients presented abnormal expression of NPY and OXT,and the concentration changes of plasma NPY and OXT will provide referential significance for the diagnosis of schizophrenia(SZ).
RESUMO
Objective To investigate the clinical significance of plasma neuropeptide Y (NPY)and oxytocin (OXT) and the mRNA level of OXT gene in first-episode schizophrenia (FES) patients and healthy controls (HC).Methods The plasma concentration of NPY and OXT in 55 FES patients and 33 HC were measured by enzyme linked immunosorbent assay (ELISA) and the mRNA level of OXT gene were performed by real-time quantitative polymerase chain reaction (RT-qPCR).Results The NPY levels in FES patients ((1386.88±254.57) pg/ml) were significantly higher than that in HC ((1 140.62±266.63)pg/ml)(P＜0.01),and both the males and females in FES patients ((1 489.97±231.06)pg/ml and (1 279.97±236.30) pg/ml) were higher than their counterparts in HC ((1 305.40 ± 238.80) pg/ml and (965.55 ±165.45) pg/ml) (P＜0.05,P＜0.01).The OXT level in FES patients ((553.26± 180.49) pg/ml) was lower than that in HC ((696.27±280.77) pg/ml) with significant difference (P＜0.05),especially the females FES patients ((597.49±178.63)pg/ml vs (785.51±329.60)pg/ml);but the mRNA expression of OXT gene in FES patients (0.2075 (0.1653,0.3388)) were significantly higher than that in HC (0.1615 (0.1321,0.2200)) (P＜0.05),and there were no differences between the females of the two groups (P＞0.05).Conclusion The FES patients presented abnormal expression of NPY and OXT,and the concentration changes of plasma NPY and OXT will provide referential significance for the diagnosis of schizophrenia(SZ).
RESUMO
Objective To investigate the clinical efficacy of ziprasidone in the treatment of first-episode schizophrenia.Methodsfrom January 2014 to June 2016to receive the treatment of patients with first-episode schizophrenia in 156 cases as the research object in the psychiatric hospital, which were randomly divided into two groups, the control group were given risperidone treatment, the observation group was treated with ziprasidone treatment, compared two groups of clinical curative effect of the treatment of patients after.ResultsThe patients in the observation group the total effective rate was 97.4%, the control group total effective rate was 89.7%;group after treatment in patients with negative symptoms score were significantly lower than the control group, with statistical significance between the two groups (P<0.05).ConclusionThe application of ziprasidone in the treatment of first-episode schizophrenia has achieved good clinical efficacy, the total effective rate of treatment is higher, and the negative symptoms are effectively controlled.
RESUMO
ObjectiveTo investigate the relationship between the serum concentration of IL-6,S100β,NT-3 and the cognitive functions in first-episode schizophrenia characterized by positive or negative symptoms.Methods44 first-episode schizophrenic patients characterized by positive symptoms (positive group),36 first-episode schizophrenic patients characterized by negative symptoms (negative group) and 50 healthy controls (controls) were collected.The serum levels of IL-6,S100β and NT-3 were measured by enzyme-linked immunosorbent assay (ELISA).The systematic evaluation tool-MCCB was applied to assess cognitive function in patients and controls.ResultsNT-3 serum levels in positive or negative groups were lower than those in controls and the differences were significant((118.39±37.50) ng/L,(112.55±32.29) ng/L vs (141.18±29.67) ng/L) (P<0.01).IL-6 and S100β serum levels in positive or negative groups were higher than those in controls and the differences were statistically significant((5.74±1.00)ng/L,(5.07±1.17)ng/L vs (4.23±0.91)ng/L),((132.98±46.71)ng/L,(124.99±43.14)ng/L vs (103.63±31.57)ng/L)(P<0.01).IL-6 serum levels in the positive group ((5.07±1.17)ng/L) were lower than those in the negative group ((5.74±0.99)ng/L) and the difference was statistically significant (P<0.05).In MCCB test,the TMT scores in patients characterize by positive symptoms or patients characterize by negative symptoms were higher than those in healthy control group (P<0.01).BACS SC,HVLT-R WMS-Ⅲ,SS,NAB,BVMT-R,CF in patients characterize by positive symptoms or by negative symptoms were lower than those in healthy control group(P<0.01).There were no statistical difference in the MCCB scores between the patients with positive symptoms and negative symptoms.In positive group,there was a positive correlation between the IL-6 serum concentration and the general symptom scores in PANSS (P<0.05).In positive group,NT-3 serum concentration was positively correlated with the general symptom scores or total scores of PANSS (P<0.05).BVMT-R scores in MCCB were also positively correlated with IL-6 or NT-3 serum concentration in positive group (P<0.05).ConclusionThe impairment of part of cognitive functions for schizophrenic patients may be related to the serum protein factors.There may be different in pathophysiology between the first-episode schizophrenic patients characterized by positive symptoms and those characterized by negative symptoms.